Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
HonorHealth · University of Arizona · +29 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
199
total citations
- FWCI
- 53.60
- Percentile
- 100%
- References
- 35
Citations per year
Authors
29- BJBradley J. MonkCorresponding
HonorHealth, University of Arizona
- TTTakafumi Toita
Okinawa Prefectural Chubu Hospital
- XWXiaohua Wu
Fudan University Shanghai Cancer Center
- JCJuan Carlos Vázquez Limón
Hospital Civil de Guadalajara, Universidad de Guadalajara
- RTR. Tarnawski
The Maria Sklodowska-Curie National Research Institute of Oncology
Topics & keywords
Topics
Keywords
- Durvalumab
- Medicine
- Placebo
- Chemoradiotherapy
- Cervical cancer
- Double blind
- Oncology
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.